Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Smoking in patients receiving psychotropic medications - A pharmacokineticperspective
Autore:
Desai, HD; Seabolt, J; Jann, MW;
Indirizzi:
Mercer Univ, So Sch Pharm, Dept Pharm Practice & Pharmaceut Sci, Atlanta, GA 30341 USA Mercer Univ Atlanta GA USA 30341 & Pharmaceut Sci, Atlanta, GA 30341 USA Univ Illinois, Coll Pharm, Chicago, IL USA Univ Illinois Chicago IL USAUniv Illinois, Coll Pharm, Chicago, IL USA Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA Univ Illinois ChicagoIL USA 60612 , Dept Psychiat, Chicago, IL 60612 USA
Titolo Testata:
CNS DRUGS
fascicolo: 6, volume: 15, anno: 2001,
pagine: 469 - 494
SICI:
1172-7047(2001)15:6<469:SIPRPM>2.0.ZU;2-C
Fonte:
ISI
Lingua:
ENG
Soggetto:
CIGARETTE-SMOKING; PLASMA-CONCENTRATIONS; TARDIVE-DYSKINESIA; PSYCHIATRIC POPULATION; REDUCED HALOPERIDOL; VARIABILITY FACTORS; DEPRESSED-PATIENTS; DRUG-INTERACTIONS; TOBACCO SMOKING; CYP1A2 GENE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
94
Recensione:
Indirizzi per estratti:
Indirizzo: Jann, MW Mercer Univ, So Sch Pharm, Dept Pharm Practice & Pharmaceut Sci, Atlanta, GA 30341 USA Mercer Univ Atlanta GA USA 30341 ceut Sci, Atlanta, GA 30341 USA
Citazione:
H.D. Desai et al., "Smoking in patients receiving psychotropic medications - A pharmacokineticperspective", CNS DRUGS, 15(6), 2001, pp. 469-494

Abstract

Many psychiatric patients smoke, and are believed to be heavier smokers than those without psychiatric disorders. Cigarette smoking is one of the environmental factors that contributes to interindividual variations in response to an administered drug. Polycyclic aromatic hydrocarbons (PAHs) presentin cigarette smoke induce hepatic aryl hydrocarbon hydroxylases, thereby increasing metabolic clearance of drugs that are substrates for these enzymes. PAHs have been shown to induce 3 hepatic cytochrome P450 (CYP) isozymes,primarily CYP1A1, 1A2 and 2E1. Drug therapy can also be affected pharmacodynamically by nicotine. The most common effect of smoking on drug disposition in humans is an increase in biotransformation rate, consistent with induction of drug-metabolising enzymes. Induction of hepatic enzymes has been shown to increase the metabolism and to decrease the plasma concentrations of imipramine, clomipramine, fluvoxamine and trazodone. The effect of smoking on the plasma concentrations of amitriptyline and nortriptyline is variable. Amfebutamone (bupropion) does not appear to be affected by cigarette smoking. Smoking is associated with increased clearance of tiotixene, fluphenazine, haloperidol and olanzapine. Plasma concentrations of chlorpromazine and clozapine are reduced by cigarette smoking. Clinically, reduced drowsiness in smokers receiving chlorpromazine, and benzodiazepines, compared withnonsmokers has been reported. Increased clearance of the benzodiazepines alprazolam, lorazepam, oxazepam, diazepam and demethyl-diazepam is found in cigarette smokers, whereas chlordiazepoxide does not appear to be affected by smoking. Carbamazepine appears to be minimally affected by cigarette smoke, perhaps because hepatic enzymes are already stimulated by its own autoinductive properties. Cigarette smoking can affect the pharmacokinetic and pharmacodynamic properties of many psychotropic drugs. Clinicians should consider smoking as an important factor in the disposition of these drugs.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 21/01/20 alle ore 00:49:40